ADReCS

Pharmaceutical Information

Drug Name	Carboplatin
Drug ID	BADD_D00364
Description	Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage	Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status	approved
ATC Code	L01XA02
DrugBank ID	DB00958
KEGG ID	D01363
MeSH ID	D016190
PubChem ID	426756
TTD Drug ID	D0X7HM
NDC Product Code	0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII	BG3F62OND5
Synonyms	Carboplatin \| cis-Diammine(cyclobutanedicarboxylato)platinum II \| CBDCA \| Paraplatin \| Paraplatine \| Platinwas \| Ribocarbo \| Carboplat \| Neocarbo \| Carbosin \| Carbotec \| Ercar \| JM-8 \| JM 8 \| JM8 \| Nealorin \| NSC-241240 \| NSC 241240 \| NSC241240 \| Blastocarb

Chemical Information

Molecular Formula	C6H12N2O4Pt
CAS Registry Number	41575-94-4
SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Cardiac failure acute	02.05.01.005	0.000112%		Not Available
Cardiac tamponade	02.06.01.001	0.000112%
Cardio-respiratory arrest	22.02.06.007; 02.03.04.002	0.001645%		Not Available
Cardiogenic shock	24.06.02.006; 02.05.01.003	0.000560%		Not Available
Cardiomyopathy	02.04.01.001	0.000280%		Not Available
Cardiovascular disorder	02.11.01.010; 24.03.02.009	0.000504%		Not Available
Carotid artery stenosis	24.04.06.001; 17.08.02.001	0.000358%		Not Available
Cerebral artery embolism	24.01.04.001; 17.08.01.001	0.000112%		Not Available
Cerebrovascular accident	24.03.05.001; 17.08.01.007	-	-
Chest discomfort	22.12.02.002; 08.01.08.019; 02.02.02.009	0.007119%		Not Available
Chest pain	22.12.02.003; 08.01.08.002; 02.02.02.011	0.005910%		Not Available
Chills	15.05.03.016; 08.01.09.001	0.004735%
Choking	22.12.03.003	0.000168%		Not Available
Choking sensation	22.12.03.004; 19.01.02.002	0.000168%		Not Available
Cholangitis	09.02.01.002	0.000112%		Not Available
Cholecystitis	09.03.01.001	0.000168%
Cholestasis	09.01.01.001	0.000336%		Not Available
Cholinergic syndrome	17.05.01.002	0.000280%		Not Available
Chronic myeloid leukaemia	01.10.07.001; 16.01.07.001	0.000280%		Not Available
Chronic obstructive pulmonary disease	22.03.01.007	0.000783%		Not Available
Circulatory collapse	24.06.02.001	0.000448%		Not Available
Cold sweat	23.02.03.002; 08.01.03.024	0.001444%		Not Available
Colitis	07.08.01.001	0.000728%
Colitis ischaemic	24.04.08.012; 07.08.01.004	0.000336%		Not Available
Compartment syndrome	24.04.05.006; 15.05.05.005	0.000112%		Not Available
Conjunctival haemorrhage	24.07.05.001; 06.07.01.001	0.000112%		Not Available
Constipation	07.02.02.001	-	-
Conversion disorder	19.24.01.001	0.000112%		Not Available
Coronary artery occlusion	12.02.01.036; 24.04.04.013; 02.02.01.006	0.000112%		Not Available
Cough	22.02.03.001	0.006391%

The 3th Page First Pre 3 4 5 6 7 Next Last Total 21 Pages